Dear colleagues,
Company Abbott has informed us, that there may be cross-reactions under Fulvestrant, in the analysis of 17-ß-estradiol.
In women, who receive Fulvestrant for therapeutic reasons due to advanced mamma carcinoma, false high 17-ß-estradiol values are seen. This may lead to wrong therapeutic decisions.
Evaluations by LC/MS (Liquid chromatography/mass spectroscopy) are not affected by cross-reactions. In women with Fulvestrant-therapy, in whom increased 17-ß-estradiol levels were measured, further testing by LC/MS is recommended.
Please note the desired method LC/MS clearly on your request form.
Should you have any further questions, please contact Dr. Juliane Fazio on tel. +49 5222 8076-207.